ABX464-102
52 evidence topics · 10 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Primary, secondary, and echocardiography objectives in the protocol
Location and study date
Results posting date
Registered location
Sites, study period, and EudraCT number in the protocol
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Interventional model description | “open-label, follow-up study” |
| Masking | “None (Open Label)” |
| Phase | “Phase 2” |
| Enrollment (actual) | “22” |
Open-label treatment for 48 months regardless of induction assignment
Data safety monitoring board and cardiovascular safety committee
Planned treatment duration of 12 months, January 2018, superseded in March 2019
Planned treatment duration of 24 months, March 2019, superseded in February 2022
Eligibility criteria
Inclusion and exclusion criteria in the ClinicalTrials.gov record
Enrollment based on willingness and investigator judgement
Enrollment of responders planned at authorization, January 2018
Treatment
Intervention in the ClinicalTrials.gov record
Allowed and prohibited concomitant medications
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Efficacy definitions in the statistical analysis plan
Changes from the protocol in the statistical analysis plan
Clinical response definition in the posted results
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Observed cases and non-responder imputation sets
Descriptive efficacy analysis planned in the protocol
Analysis populations in the posted results
Results
Participant disposition
Participants entering from the obefazimod and placebo induction groups
Participants remaining on treatment through year 2
Baseline characteristics
Demographics in the posted results
| Characteristic | ABX464 50 mg (N=22) |
|---|---|
| Age, years, mean (SD) | “42.4(14.3)” |
| Female | “9” |
| Male | “13” |
| White | “22” |
Clinical remission status at entry among participants remaining at month 12
Efficacy results
Month 48 outcomes with non-responder imputation in the posted results
| Outcome (N=22) | Quoted record |
|---|---|
| Participants with clinical response | “11” |
| Participants with clinical remission | “9” |
| Participants with endoscopic improvement | “9” |
| Participants with endoscopic remission | “6” |
| Change in total Mayo score, mean (SD) | “-3.0(3.4)” |
| Change in partial Mayo score, mean (SD) | “-2.2(2.4)” |
| Change in fecal calprotectin, µg/g, mean (SD) | “-299.69(472.28)” |
| Change in CRP, mg/L, mean (SD) | “2.29(4.82)” |
| Change in ESR, mm/hour, mean (SD) | “2.90(8.62)” |
Ulcerative colitis worsening reported as an adverse event (post hoc)
Month 12 interim results
Month 12 interim results stated in the protocol
Month 24 interim results with central endoscopy reading
Health-related quality of life and patient-reported outcomes
SF-36 component scores at up to 24 months in the posted results
| Outcome (N=22, non-responder imputation) | Change from day 0, mean (SD) |
|---|---|
| SF-36 physical component | “4.82(4.23)” |
| SF-36 mental component | “6.38(3.40)” |
SF-36 instrument and assessment schedule
Safety results
Adverse event counts in the posted results
Deaths and serious adverse events in the posted results
| Measure | Affected / at risk (%) |
|---|---|
| All-cause mortality | “0/22 (0.00%)” |
| Serious adverse events, total | “3/22 (13.64%)” |
| Myocardial infarction | “1/22 (4.55%)” |
| Enteropathic spondylitis | “1/22 (4.55%)” |
| Benign ovarian tumor | “1/22 (4.55%)” |
Investigator assessment of the serious adverse events
Other adverse events in at least 3 participants
| Event | Affected / at risk (%) |
|---|---|
| Other (not including serious) adverse events, total | “20/22 (90.91%)” |
| Colitis ulcerative | “7/22 (31.82%)” |
| Abdominal pain | “5/22 (22.73%)” |
| Nasopharyngitis | “5/22 (22.73%)” |
| Diarrhoea | “4/22 (18.18%)” |
| Vomiting | “3/22 (13.64%)” |
| Headache | “3/22 (13.64%)” |
Sponsor statements on safety at month 12 and year 2
Study limitations
Summary
ABX464-102 was a single-group, open-label extension without a control group, in which 22 participants who completed ABX464-101 (15 previously assigned to obefazimod and 7 to placebo) received obefazimod 50 mg once daily, at sites in Belgium, Hungary, and Poland (3, 9, and 10 participants). Enrollment was based on participant willingness and investigator judgement, and the protocol set no sample size beyond a “Maximum 30 subjects”. The planned treatment period was 12 months in a 2018 press release, 24 months after a data safety monitoring board recommendation reported in 2019, and 48 months in the 2022 protocol. The primary endpoint was the number of treatment-emergent adverse events; efficacy results were to be “presented descriptively”. Eleven of 22 participants completed the study. Interim efficacy was reported among participants with an endoscopy at each timepoint (12 of 16 in clinical remission at month 12, 11 of 16 at month 24, and 11 of 13 at month 36); endoscopies were read locally at month 12 and centrally at month 24. In the posted non-responder imputation analysis, 9 of 22 participants were in clinical remission at month 48. The statistical analysis plan defines clinical response by the modified Mayo score, and the posted outcome description defines it by the total Mayo score. Seven of 22 participants had ulcerative colitis worsening reported as an adverse event. SF-36 was assessed only to month 24, and the echocardiography endpoints were moved to a separate report that was not located. All 22 participants were White.